A phase I/II trial to investigate the safety and efficacy of OPX-212 in neuromyelitis optica

Trial Profile

A phase I/II trial to investigate the safety and efficacy of OPX-212 in neuromyelitis optica

Planning
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2015

At a glance

  • Drugs OPX 212 (Primary)
  • Indications Neuromyelitis optica
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 10 Nov 2015 Planned initiation date changed from 1 Aug 2015 to 1 Jan 2016, according to a Opexa Therapeutics media release.
    • 10 Nov 2015 Opexa Therapeutics expects to submit the IND to the US FDA and start this study in the first half of 2016, according to the company media release.
    • 26 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top